OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Mark Scholz on Advances in Prostate Cancer Imaging

May 10th 2013

Mark C. Scholz, MD, from Prostate Oncology Specialists Inc, describes his excitement over advances in prostate cancer imaging techniques, specifically those involving multiparametric MRI.

Donna L. Berry on Listening to Cancer Patients

May 10th 2013

Donna L. Berry, PhD, RN, AOCN, FAAN, Director, Phyllis F. Cantor Center for Research in Nursing & Patient Care Services, Dana-Farber Cancer Institute, discusses the importance of listening to patients with cancer.

Dr. Concepcion on the AUA PSA Screening Guidelines

May 9th 2013

Raoul S. Concepcion, MD, from Urology Associates, PC, discusses the new guidelines on prostate cancer screening that were issued by the American Urological Association.

Dr. Jennifer Brown Discusses Rituximab and Ibrutinib in CLL

May 9th 2013

Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses the use of rituximab and ibrutinib in chronic lymphocytic leukemia.

Dr. Muss on Using Tools to Evaluate Older Patients

May 9th 2013

Hyman B. Muss, MD, Professor of Medicine, Director of Geriatric Oncology, Lineberger Comprehensive Cancer Center, discusses evaluation tools for treating older patients.

Dr. Gomella on AUA's New Prostate Cancer Guidelines

May 8th 2013

Leonard G. Gomella, MD, from the Thomas Jefferson University Hospital Kimmel Cancer Center, discusses the clinical guidelines released by the American Urological Association at its 2013 Annual Meeting.

Dr. Mesa on Ruxolitinib in Chronic Myeloid Leukemia

May 8th 2013

Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, discusses the mechanism of action of ruxolitinib in chronic myeloid leukemia.

Dr. Camidge on Targeted Therapies in Adjuvant NSCLC

May 7th 2013

D. Ross Camidge, MD, PhD, from the University of Colorado Cancer Center, discusses the selective administration of targeted therapies in the adjuvant setting for patients with non-small cell lung cancer.

Dr. von Minckwitz on Breast Cancer Responses

May 7th 2013

Gunter von Minckwitz, MD, PhD, discusses the current unsolved medical situation regarding patients with breast cancer who do not respond to treatment.

Dr. Vogelzang Discusses First-Line Axitinib in mRCC

May 6th 2013

Nicholas J. Vogelzang, MD, from the Comprehensive Cancer Centers of Nevada, discusses the comparison of axitinib to sorafenib as first-line therapy in patients with metastatic renal cell carcinoma.

Dr. Advani Discusses Front-Line Brentuximab

May 6th 2013

Ranjana Advani, MD, Professor of Medicine and Oncology, Stanford University, discusses the movement of brentuximab vedotin combined with CHOP to the front-line.

Dr. Petrylak Describes the Investigation of PROSTVAC

May 3rd 2013

Daniel P. Petrylak, MD, from the Smilow Cancer Center at Yale-New Haven, describes the clinical investigation of the immunotherapeutic vaccine PROSTVAC in men with castration-resistant prostate cancer.

Dr. Tripathy Reviews Targeted Therapies in Breast Cancer

May 3rd 2013

Debu Tripathy, MD, from the University of Southern California Norris Comprehensive Cancer Center, discusses the targeted therapies that are currently available for the treatment of patients with breast cancer.

Dr. Tanyi Describes a Novel Two-Step Immunotherapy

May 2nd 2013

Janos L. Tanyi, MD, PhD, from the University of Pennsylvania, discusses two phase I studies that examined a novel two-step immunotherapy for women with advanced ovarian cancer.

Dr. Carey on the Future of Clinical Trial Design

May 2nd 2013

Lisa A. Carey, MD, Professor of Medicine, University of North Carolina at Chapel Hill, discusses the present and future state of clinical trial design.

Dr. Melnick on the Epigenetic Basis of B-Cell Lymphomas

May 2nd 2013

Ari M. Melnick, MD, Professor of Medicine, Weill Cornell Medical College, discusses his presentation on the epigenetic basis of B-cell lymphomas at the 17th International Congress on Hematologic Malignancies.

Dr. Sandler on Orteronel in High-Risk Prostate Cancer

May 1st 2013

Howard M. Sandler, MD, from the Cedars-Sinai Medical Center, describes his excitement over research into new agents that modulate the androgen axis in prostate cancer.

Dr. Cheson on Targeting PD-1 in Hematologic Malignancies

May 1st 2013

Bruce D. Cheson, MD, from the Georgetown Lombardi Comprehensive Cancer Center, discusses the investigation of PD-1 targeted agents as treatments for patients with lymphoma.

Dr. Herbst on Selecting Patients for Molecular Testing

April 30th 2013

Roy S. Herbst, MD, PhD, from the Yale Cancer Center, discusses determining the eligibility of patients with non-small cell lung cancer for molecular testing.

Dr. Esserman on Screening Patients With Higher-Risk DCIS

April 30th 2013

Laura Esserman, MD, MBA, Professor, University of California, San Francisco, discusses screening patients with higher-risk DCIS.

x